Lazard terminates banker after alleged 'inappropriate' behavior: WSJ
Lazard Ltd (LAZ) has terminated the employment of Reid Snellenbarger, co-head of North America restructuring, after he allegedly acted improperly toward co-workers at a party he held this past weekend, The Wall Street Journal reported Thursday. A spokesperson for Snellenbarger did not comment, the newspaper reported. Citing people familiar with the situation, the WSJ reported that he had asked people to join him at a gathering that was not sponsored by Lazard. The bank told employees on Sunday it had fired a managing director who acted "in a manner both inappropriate and incompatible with our values," according to an internal memo seen by the WSJ. The memo from incoming CEO Peter Orszag did not name Snellenbarger, who worked at the bank's Chicago office and joined the firm in April after 18 years at Houlihan Lokey (HLI). The article did not provide any further details on Snellenbarger's alleged actions.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-06-23 0703ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?